Suchergebnisse - "Spiekermann, Karsten"

PubPharm (14)

1

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

enthalten in: Blood | 2023

von Roas, M. | Vick, B. | Kasper, M. | +21

2

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

enthalten in: Blood | 2013

von Opatz, S. | Polzer, H. | Herold, T. | +20

3

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

enthalten in: Blood | 2012

von Schneider, F. | Hoster, E. | Unterhalt, M. | +17

4

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML

enthalten in: Blood | 2012

von Leischner, H. | Albers, C. | Grundler, R. | +7

5

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

enthalten in: Blood | 2009

von Schneider, F. | Hoster, E. | Unterhalt, M. | +17

6

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

enthalten in: Blood | 2008

von Metzeler, K. | Hummel, M. | Bloomfield, C. | +19

7

Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential

enthalten in: Blood | 2007

von Vempati, S. | Reindl, C. | Kaza, S. | +7

8

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML

enthalten in: Blood | 2006

von Reindl, C. | Bagrintseva, K. | Vempati, S. | +6

9

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

enthalten in: Blood | 2006

von Schnittger, S. | Kohl, T. | Haferlach, T. | +4

10

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)

enthalten in: Blood | 2005

von Bagrintseva, K. | Geisenhof, S. | Kern, R. | +5